AhR and Pulmonary Hypertension: Role, Mechanisms, and Therapeutic Potential

The aryl hydrocarbon receptor (AhR) is a transcription factor that plays a crucial role in regulating various physiological and pathological processes, including immune response, detoxification, and cell proliferation. Recent studies have shown that AhR is also involved in the pathogenesis of pulmonary hypertension (PH), a progressive and life-threatening disease characterized by increased pulmonary artery pressure and vascular remodeling.

Activation of AhR has been shown to contribute to the development of PH by promoting inflammation, endothelial dysfunction, and smooth muscle cell proliferation. AhR activation also increases the levels of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), which play a critical role in the pathogenesis of PH.

In addition, AhR activation can induce the expression of genes involved in cell proliferation and angiogenesis, such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which contribute to the vascular remodeling and pulmonary hypertension.

Several studies have shown that AhR antagonists can attenuate the development of PH in animal models, suggesting that targeting AhR may be a potential therapeutic strategy for this disease. However, further research is needed to fully understand the role of AhR in PH and to develop effective AhR-targeted therapies for this devastating disease.